IBD Flashcards
UC:
What therapy is superior for induction of remission in mild to moderately active ulcerative colitis compared with oral or topical therapies alone?
Combined mesalamine therapy (oral and topical)
Crohn
Tx of mild to moderate disease (NO fever or abdominal tenderness, <10% weight loss)
- Budesonide or mesalamine (for limited, mild ileocolonic disease) for remission
- 6MP, azathioprine, or MTX for maintenance
Crohn
Tx of moderate to severe disease (fever, >10% weight loss, anemia, abdominal pain, nausea, vomiting)
- prednisone for remission induction
- 6MP, azathioprine, or MTX for maintenance
- Anti-TNF antibodies in glucocorticoid refractory disease (infliximab, adalimumab, certolizumab); ustekinumab and vedolizumab for disease refractory to anti-TNF antibodies
Crohn
Tx of severe to fulminant disease (despite oral glucocorticoids, high fever, cachexia, vomiting, rebound tenderness, obstruction, or abscess)
- IV glucocorticoid for remission
- Anti-TNF antibodies in glucocorticoid refractory disease (infliximab, adalimumab, certolizumab); ustekinumab and vedolizumab for disease refractory to anti-TNF antibodies
- surgical intervention if pt has extremely toxic disease or does not benefit from medications
Crohn
Tx of fistula
azathioprine, 6MP, anti-TNF antibodies
UC
Tx of mild disease (<4 BMs a day; occasional blood in stool; normal vital signs, hemoglobin, and ESR)
5-ASA agents: mesalamine for pancolitis (combined oral and topical) and topical sulfasalazine for proctitis or left-sided colitis
UC
Tx of moderate disease
- prednisone or budesonide for remission induction
- maintenance therapy with a 5-ASA agent (topical and oral), 6-MP, or azathioprine
UC
Tx of severe disease: >6 BMs a day; bleeding, fever, pulse rate >90/min, ESR>30, anemia
- IV glucocorticoids followed by anti-TNF antibody
- surgery for refractory disease and toxic megacolon
Persons with chronic inflammatory bowel disease or who are immunocompromised are most susceptible to severe travelers’ diarrhea or complications, and prophylaxis with ***should be provided to these patients.
fluoroquinolones preferred, such as ciprofloxacin